Navigation Links
Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study
Date:1/6/2014

ocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's VMAT2 program and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's VMAT2 program include, but are not limited to; risk that NBI-98854 will not proceed to later stage clinical trials and risk that the Company's clinical trials will fail to demonstrate that NBI-98854 is safe and effective. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate partners for development, commercial manufacturing and marketing and sales activities for the Company's partnered programs; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2012 and on Form 10-Q for the quarter ended September 30, 2013. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neurocrine Biosciences To Present At Oppenheimers 24th Annual Healthcare Conference
2. Neurocrine Biosciences Announces Conference Call And Webcast To Present Third Quarter 2013 Financial Results
3. Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine
4. Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia
5. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
6. Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
7. Neurocrine Biosciences to Present at the Jefferies 2013 Global Healthcare Conference
8. Neurocrine Biosciences to Present At The Deutsche Bank 38th Annual dbAccess Health Care Conference
9. Neurocrine Biosciences Reports First Quarter 2013 Results
10. Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference
11. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014 /CNW/ -   ... after Health Canada tests confirmed it contains two undeclared ... and phenylpropylmethylamine). The distributor, Empire Health Distribution of ... from retail stores across Canada . ... for weight loss and increased energy. ...
(Date:12/24/2014)... BUFFALO, N.Y. , Dec. 24, 2014 ... been dosed with KX2-361 at Roswell Park Cancer Institute. ... a small molecule drug that has shown potent inhibitory ... lines, including those that are resistant to Temozolomide (T98G), ... malignant glioma. In a well-established brain tumor mouse model, ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... 2,050,000 shares of its common stock and Series ... common stock.  Funds under the management of QVT ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
(Date:12/26/2014)... The Biofeedback Federation of Europe annual meeting ... Rome, Italy and is hosted by the Salesian Pontifical ... a wide variety of topics such as ADHD, anxiety, ... in athletes. The scientific program will feature the latest ... allows clients to see what is going on in ...
(Date:12/26/2014)... 26, 2014 DW-InductionHeating.com (DaWei Induction Heating ... researching and developing, producing and marketing of a series ... business announces their new series of induction brazing ... the company, induction brazing refers to the ... filler material and heat. The manager says that there ...
(Date:12/25/2014)... 2014 The report “Nintedanib (Colorectal ... focuses on the current treatment landscape, unmet needs, ... cancer market. Stivarga is a drug which is ... cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), an ... refractory CRC in the US, Europe, and Japan. ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online ... its collection of discounted prom dresses, most of which ... spokesman of the company, the promotion is valid until ... to expand the UK market. , The prom dresses ... lengths, and styles: A-line strapless, empire strapless chiffon, one ...
(Date:12/25/2014)... 25, 2014 When head lice hits a ... a frenzy to get rid of it while keeping it ... Coral Gables now have the solution right in their neighborhood: ... location, Lice Troopers provides full spectrum head lice screening and ... area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2
... in Federal Funds Awarded to Reconstruct Devastating,Injuries;, ... HEIGHTS, Ill., April 17 Members of,the American ... pivotal role,over the next five years developing groundbreaking ... Iraq and Afghanistan. The U.S.,Department of Defense (DoD) ...
... for cosmetic purposes might also improve wound healing and ... scarred during combat. Dr. Adam Katz, plastic surgeon and ... conduct research in this area under the Armed Forces ... announce the formation of AFIRM, which has received more ...
... CARLSBAD, Calif., April 17 The National Center ... resource for autism research, education and family support,services ... Families are,flocking to NCARE resulting from the announcement ... is that families desperately need centralized,autism resources., ...
... With Information and,Best Practices Related to Upcoming ... April 17 The new Centers for,Medicare ... eliminate or,reduce payments for three hospital-acquired infections ... conference for healthcare executives and professionals,sponsored by ...
... The National,Association of Specialty Health Organizations ... Innovation Award. The recipient of the award,will ... through,innovative programs and practices., (Logo: ... for the specialty health industry, we felt ...
... April 17 MSA (NYSE: MSA ), the,global ... that protect people,s health and safety, announced today that ... live via the,Internet on Thursday, May 1, 2008 at ... Investors and interested parties will have the opportunity ...
Cached Medicine News:Health News:Plastic Surgeons Play Pivotal Role in War Injury Research 2Health News:Plastic Surgeons Play Pivotal Role in War Injury Research 3Health News:UVA Health System part of Armed Forces multi-million dollar effort to help soldiers 2Health News:California's First Non-profit Center for Autism Research, Education and Family Services 2Health News:APIC Conference to Address New CMS Regulations 2Health News:The National Association of Specialty Health Organizations to Recognize Excellence in Technology Education With Industry Award 2Health News:MSA Schedules First Quarter Earnings Webcast 2
Lightweight PVC housing for easy transport, integrated handle. Easy lamp exchange....
... important diagnostic tool in determining functionality ... important when deciding courses of treatment ... treatment, recurring infections and autoimmune dieseases. ... patients with autoimmune diseases giving rise ...
Maximum brightness, durability, universal power suply, microprocessor-controlled light output and, in the event of lamp failure or degredation, automatic switchover to an integraged spare lamp....
Tested by surgeons for functionality and ergonomy. Uses the Medifix C3-3001-3CCD camera head....
Medicine Products: